KARYOPHARM THERAPEUTICS INC (KPTI) Stock Price & Overview
NASDAQ:KPTI • US48576U2050
Current stock price
The current stock price of KPTI is 5.89 USD. Today KPTI is up by 1.2%. In the past month the price decreased by -33.22%. In the past year, price increased by 52.59%.
KPTI Key Statistics
- Market Cap
- 108.023M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -13.13
- Dividend Yield
- N/A
KPTI Stock Performance
KPTI Stock Chart
KPTI Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to KPTI. When comparing the yearly performance of all stocks, KPTI is one of the better performing stocks in the market, outperforming 71.28% of all stocks.
KPTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to KPTI. KPTI may be in some trouble as it scores bad on both profitability and health.
KPTI Earnings
On February 12, 2026 KPTI reported an EPS of -2.22 and a revenue of 34.08M. The company missed EPS expectations (-9.14% surprise) and missed revenue expectations (-4.84% surprise).
KPTI Forecast & Estimates
13 analysts have analysed KPTI and the average price target is 15.71 USD. This implies a price increase of 166.69% is expected in the next year compared to the current price of 5.89.
For the next year, analysts expect an EPS growth of 60.72% and a revenue growth -5.58% for KPTI
KPTI Groups
Sector & Classification
KPTI Financial Highlights
Over the last trailing twelve months KPTI reported a non-GAAP Earnings per Share(EPS) of -13.13. The EPS decreased by -30.65% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -180.82% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
KPTI Ownership
KPTI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About KPTI
Company Profile
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
Company Info
IPO: 2013-11-06
KARYOPHARM THERAPEUTICS INC
85 Wells Avenue, Second Floor
Newton MASSACHUSETTS 02459 US
CEO: Michael G. Kauffman
Employees: 228
Phone: 13026587581
KARYOPHARM THERAPEUTICS INC / KPTI FAQ
Can you describe the business of KARYOPHARM THERAPEUTICS INC?
Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is headquartered in Newton, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2013-11-06. The firm is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The firm is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.
What is the current price of KPTI stock?
The current stock price of KPTI is 5.89 USD. The price increased by 1.2% in the last trading session.
What is the dividend status of KARYOPHARM THERAPEUTICS INC?
KPTI does not pay a dividend.
What is the ChartMill rating of KARYOPHARM THERAPEUTICS INC stock?
KPTI has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for KPTI stock?
13 analysts have analysed KPTI and the average price target is 15.71 USD. This implies a price increase of 166.69% is expected in the next year compared to the current price of 5.89.
How is the valuation of KARYOPHARM THERAPEUTICS INC (KPTI) based on its PE ratio?
KARYOPHARM THERAPEUTICS INC (KPTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-13.13).
What is the ownership structure of KARYOPHARM THERAPEUTICS INC (KPTI)?
You can find the ownership structure of KARYOPHARM THERAPEUTICS INC (KPTI) on the Ownership tab.